Akero Therapeutics, Inc. — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-12-21

Reporting Person: White William Richard (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-21	Common Stock	M	100	$7.009	Acquired	3377	Direct
2021-12-21	Common Stock	S	100	$22.00	Disposed	3277	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-21	Stock Option (Right to Buy)	$7.009	M	100	Disposed	2029-04-04	Common Stock (100)	Direct

Footnotes

F1: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person.

F2: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.